292
Views
14
CrossRef citations to date
0
Altmetric
Original Article

18F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma

, , , , &
Pages 494-499 | Received 06 Aug 2014, Accepted 18 Sep 2014, Published online: 05 Mar 2015

References

  • RSiegel, DNaishandham, AJemal. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
  • EGTroost, DASchinagl, JBussink, OCBoerman, AJvan der Kogel, WJOyen, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010;51:66–76.
  • GMiyashita, THiguchi, NOriuchi, YArisaka, HHanaoka, HTominaga, et al. 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry. Ann Nucl Med 2010;24:579–84.
  • ANobusawa, MKim, KKaira, GMiyashita, ANegishi, NOriuchi, et al. Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2013;40:1692–700.
  • KKaira, YSunose, KArakawa, TOgawa, NSunaga, KShimizu, et al. Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer 2012;107:632–8.
  • OYanagida, YKanai, AChairoungdua, DKKim, HSegawa, TNii, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 2001;1514:291–302.
  • HImai, KKaira, NOriuchi, NYanagitani, NSunaga, TIshizuka, et al. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology 2009;54:804–13.
  • DKKim, SGAhn, JCPark, YKanai, HEndou, JHYoon. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesions. Anticancer Res 2004;24:1671–6.
  • MToyoda, KKaira, YOhshima, NSIshioka, MShino, KSakakura, et al. Prognostic significance of amino acid transporter expression (LAT1, ASCT2 and xCT) in surgically resected tongue cancer. Br J Cancer 2014;110:2506–13.
  • SRMartens-de Kemp, ABrink, MStigter-van Walsum, JMDamen, FRustenburg, TWu, et al. CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res 2013;10:477–88.
  • KKaira, NOriuchi, NSunaga, TIshizuka, KShimizu, NYamamoto. A systemic review of PET and biology in lung cancer. Am J Transl Res 2011;3:383–91.
  • KKaira, MEndo, MAbe, KNakagawa, YOhde, TOkumura, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010;28:3746–53.
  • AMiyawaki, RIkeda, HHijioka, TIshida, MUshiyama, ENozoe, et al. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemotherapy for oral squamous cell carcinoma. Oncol Rep 2010;23:1205–12.
  • AMGroves, MShastry, MRodriguez-Justo, AMalhotra, REndozo, TDavidson, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging 2011;38:46–52.
  • MTian, HZhang, YNakasone, KMogi, KEndo. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004;31:5–12.
  • MTian, HZhang, THiguchi, NOriuchi, YNakasone, KTakata, et al. Hexokinase-II expression in untreated oral squamous cell carcinoma: comparison with FDG PET imaging. Ann Nucl Med 2005;19:335–8.
  • AArgiris, MVKaramouzis, WEGooding, BFBranstetter, SZhong, LERaez, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140–5.
  • GMarioni, AStaffieri, EFasanaro, RStramare, LGiacomelli, EBernardi, et al. The role of angiogenin in pT1-T2 tongue carcinoma neo-angiogenesis and cell proliferation: an exploratory study. J Oral Pathol Med 2013;42:606–11.
  • BBKoolen, MJVrancken Peeters, JWesseling, EHLips, WVVogel, TSAukema, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2012;39:1830–8.
  • AWSauter, SWinterstein, DSpira, JHetzel, MSchulze, MMueller, et al. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med 2012;53:521–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.